Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. has announced its unaudited interim results for the first half of 2025, showing a decrease in revenue and profit compared to the same period last year. Despite a reduction in costs, the company experienced a decline in gross profit and operating profit, reflecting challenges in maintaining its financial performance amidst market conditions.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint-stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is involved in the distribution and retail of pharmaceutical and healthcare products, with a market focus that extends to Hong Kong.
YTD Price Performance: -4.64%
Average Trading Volume: 5,952,326
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.91B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.